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Abstract
Equine encephalomyelitis (Eastern and Western) has been assessed according to the criteria of the
Animal Health Law (AHL), in particular criteria of Article 7 on disease proﬁle and impacts, Article 5 on
the eligibility of equine encephalomyelitis (Eastern and Western) to be listed, Article 9 for the
categorisation of equine encephalomyelitis (Eastern and Western) according to disease prevention and
control rules as in Annex IV, and Article 8 on the list of animal species related to equine
encephalomyelitis (Eastern and Western). The assessment has been performed following a methodology
composed of information collection and compilation, expert judgement on each criterion at individual
and, if no consensus was reached before, also at collective level. The output is composed of the
categorical answer, and for the questions where no consensus was reached, the different supporting
views are reported. Details on the methodology used for this assessment are explained in a separate
opinion. According to the assessment performed, equine encephalomyelitis (Eastern and Western) can
be considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL. The
disease would comply with the criteria as in Section 5 of Annex IV of the AHL, for the application of the
disease prevention and control rules referred to in point (e) of Article 9(1). The assessment here
performed on compliance with the criteria as in Section 4 of Annex IV referred to in point (d) of Article 9
(1) is inconclusive. The animal species to be listed for equine encephalomyelitis (Eastern and Western)
according to Article 8(3) criteria are several species of mammals, birds, reptiles and amphibians as
susceptible species; rodents, lagomorphs and several bird species as reservoirs and at least four
mosquito species (family Culicidae) as vectors.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The background and Terms of Reference (ToR) as provided by the European Commission for the
present document are reported in Section 1.2 of the scientiﬁc opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria of
Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL) framework (EFSA
AHAW Panel, 2017a).
1.2. Interpretation of the Terms of Reference
The interpretation of the ToR is as in Section 1.2 of the scientiﬁc opinion on the ad hoc
methodology followed for the assessment of the disease to be listed and categorised according to the
criteria of Article 5, Annex IV according to Article 9, and 8 within the AHL framework (EFSA AHAW
Panel, 2017a).
The present document reports the results of assessment on equine encephalomyelitis (Eastern and
Western) according to the criteria of the AHL articles as follows:
• Article 7: equine encephalomyelitis (Eastern and Western) proﬁle and impacts
• Article 5: eligibility of equine encephalomyelitis (Eastern and Western) to be listed
• Article 9: categorisation of equine encephalomyelitis (Eastern and Western) according to
disease prevention and control rules as in Annex IV
• Article 8: list of animal species related to Equine encephalomyelitis (Eastern and Western)
2. Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the
ad hoc method developed for assessing any animal disease for the listing and categorisation of
diseases within the AHL framework (EFSA AHAW Panel, 2017a).
3. Assessment
3.1. Assessment according to Article 7 criteria
This section presents the assessment of equine encephalomyelitis (Eastern and Western) according
to the Article 7 criteria of the AHL and related parameters [see table 2 of the opinion on methodology
(EFSA AHAW Panel, 2017a)], based on the information contained in the fact-sheet as drafted by the
selected disease scientist (see Section 2.1 of the scientiﬁc opinion on the ad hoc methodology) and
amended by the AHAW Panel.
3.1.1. Article 7(a) Disease Proﬁle
Eastern Equine Encephalitis (EEE) and Western Equine Encephalitis (WEE) are caused by infection
with EEE virus (EEEV) or WEE virus (WEEV), respectively. Both of them are Alphavirus in the
Togaviridae family. EEEV is composed by several lineages distributed in North America (lineage I) or
South America [lineages II, III and IV, named recently as Madariaga virus (MADV)].
EEEV is maintained in North America between passerine birds and Culiseta melanura mosquitoes
and wild birds. In South America, the cycle is not well established but it seems that Culex
(Melanoconion) mosquitoes and rodents/marsupials play an important role.
WEEV is maintained by Culex tarsalis and passerine birds although domestic and wild birds and
lagomorphs and rodents and Aedes mosquitoes could also be involved.
Both viruses have a single-stranded, positive-sense RNA genome and the particles are enveloped,
spherical and have a diameter of 60–65 nm.
3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
EEEV can infect horses (causing severe disease) (Carrera et al., 2013). Other species such as
white-tailed deer (Odocoileus virginianus) (Tate et al., 2005; Schmitt et al., 2007), cattle, sheep and dogs
(McGee et al., 1992; Acha and Szyfres, 2003; Pfeffer and Dobler, 2010; Zacks and Paessler, 2010; OIE,
2013; Hubalek et al., 2014; Arechiga-Ceballos and Aguilar-Setien, 2015) or African penguins (Spheniscus
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demersus) (Tuttle et al., 2005) are susceptible to infection. However, the virus can also infect reptiles,
amphibians and rodents (Bingham et al., 2012; Graham et al., 2012).
It seems that two different reservoirs are involved in the cycle of EEEV: passerine birds in North
America and some rodents and/or marsupials in South America (Mesa et al., 2005; Go et al., 2014).
Mature cotton rats (from the genus Sigmodon) experimentally infected with Madariaga strains
developed symptoms, while infection with North American (NA) strains of EEEV resulted in death
(Arrigo et al., 2010). This difference was also seen with common marmosets, since when infected by
MADV, viraemia was observed during 2 or 4 days after infection and the virus was not detected in any
tissue at the time of sacriﬁce or death. When infected by NA strains they developed no viraemia and
the virus was detected mainly in brain but also in liver and muscle at 4–5 days after infection (Adams
et al., 2008).
Several amphibians and mammals were experimentally infected by EEEV and most of them were
refractory to the virus (Hayes et al., 1964). Experimental infection has been carried out also with
house sparrows (Passer domesticus) (Arrigo et al., 2010), mice (Gardner et al., 2009), turkeys (Guy
et al., 1993), emus (genus Dromaius) (Tengelsen et al., 2001), horses, calf, crows (genus Corvus),
great-horned owls (Bubo virginianus) and pheasants (subfamily Phasianinae) (Satriano et al., 1958),
green anole (Anolis carolinensis) and garter snake (Thamnophis sirtalis) (White et al., 2011), pigs and
burros (Sudia et al., 1956; Byrne et al., 1964; Walton et al., 1989; Elvinger et al., 1996).
Passerine birds, ground squirrel (Citellus richardsoni), black-tailed jackrabbit (Lepus californicus
californicus) and probably snakes and frogs are infected by WEEV which also causes illness in horses
and humans (Hardy et al., 1977; Acha and Szyfres, 2003; Hubalek et al., 2014) although both species
are considered as dead-end hosts (Acha and Szyfres, 2003; Mesa et al., 2005; OIE, 2013). While the
natural reservoir in North America are different species of birds it seems in South America, rodents
such as rice rats (Oryzomys spp.), rabbits and Lepus europaeus (Monath et al., 1985; Acha and
Szyfres, 2003; Pfeffer and Dobler, 2010; Zacks and Paessler, 2010; OIE, 2013; Hubalek et al., 2014;
Arechiga-Ceballos and Aguilar-Setien, 2015) play this role.
Rabbits (Gresikova and Zavada, 1966), ponies (Sponseller et al., 1966) and blacktail jackrabbits
(Hardy et al., 1977) have been experimentally infected by WEEV.
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Outbreaks of EEE in horses in North America are common and often accompanied by high case
fatality rates: 80–90% of the infected horses develop acute and lethal disease, and about 66% of the
survivors develop neurological sequelae (Scott and Weaver, 1989) as seen in Texas and Louisiana in
1947 when an estimated 14,334 horses and mules were infected and 11,727 died (Scott and Weaver,
1989). In South America before year 2000, few epizootics of MADV were recorded, but in 2008 and
2009 larger outbreaks occurred. In Brazil, 229 horses were affected with a case fatality rate of 73%
and disease severity similar to that of North America (Long, 2015).
Clinical signs for horses infected by EEEV or WEEV are similar causing a disease named ‘sleeping
sickness’ although the mortality is lower for WEEV which generally causes a mild disease after a short
incubation period (5–15 days) with fever, malaise, headache, nausea, vomiting and anorexia. In some
cases, symptoms of altered mental status, weakness and signs of meningeal irritation occurs and a
minority of infected individuals develop encephalitis or encephalomyelitis.
The case fatality rate associated to WEEV in horses is about 20–30% (Acha and Szyfres, 2003;
CFSPH, 2015). Associated mortality by EEEV infection in pheasants or emus could be as high as
75–87% (Scott and Weaver, 1989; Acha and Szyfres, 2003; Hubalek et al., 2014; CFSPH, 2015).
A decline to fewer than 10 cases per year in the annual number of cases due to WEEV has been
observed in the USA since 1988 and no human or animal cases have been reported since 2003 (Zacks
and Paessler, 2010), with no reported cases to the Centers for Disease Control and Prevention (CDC)
in the period 2003–2016 (CDC/USGS, online-a). By reviewing available epidemiological data, Zacks and
Paessler have estimated the average number of sick horses per year in 0–5 for WEEV and 120 for EEV
(Zacks and Paessler, 2010).
No clear data about prevalence or case-morbidity rate are available for these viruses.
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3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
Presence
Parameter 1 – Report of zoonotic human cases (anywhere)
EEEV and WEEV are zoonoses and outbreaks in equids usually preceded, by one or several weeks,
the emergence of human cases. In 1938, in Massachusetts, 34 cases with 25 deaths were reported,
and in 1959 in New Jersey, 32 cases occurred (CDC, 2012, 2013, online-c). Furthermore, CDC reported
that 220 conﬁrmed human cases of EEE occurred in the U.S. between the years 1964 and 2004 (CDC,
2012, 2013, online-c). Of the 15 EEE cases in children reported in New Hampshire and Massachusetts
between 1970 and 2010, seven were associated with mental disability, with only four of those cases
improving (Silverman et al., 2013). A recent outbreak in Panama of EEE/Venezuelan equine
encephalitis (VEE) in 2010 recorded 99 acute infection cases, where eight patients 1–13 years of age
experienced neurological sequelae. The most common sequelae were seizures, which initially occurred
in 63% of patients (Carrera et al., 2013).
In recent years, it seems that human cases of EEE are more frequent and have extended
northward in New England (Armstrong and Andreadis, 2013; Oliver et al., 2016; CDC/USGS, online-b).
Human cases in USA reported from 2004 to 2013 are summarised in Table 1 (CDC, online-d).
Between 1964 and 2010, 640 cases of WEE were reported in the United States by the CDC (online-c)
and it was concluded that children older than 14 years of age have a higher chance of acquiring WEEV
infection. Cases have dwindled over the past few years for as yet undetermined reasons, but a drop in
viral virulence is not considered to underlie this trend (Forrester et al., 2008). No human cases have been
reported in USA since 2003 (CDC/USGS, online-a). Although the mortality rate for WEE is low, upwards of
30% of infections develop neurological sequelae. Between 1939 and 1956, there were 636 recorded
cases of WEE in the United States and Canada, of which 86 cases had sequelae. The frequency of these
sequelae in children under one year of age was greater than 50 (Herzon et al., 1957).
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Parameter 1 – Resistant strain to any treatment even at laboratory level
No speciﬁc treatment for EEE or WEE is available.
3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the
environment
Animals are infectious during the viraemic period for a period that in most cases has been
determined in some species through experimental infections that are summarised in the table below
(Table 2). No data about the duration of the latent period is available.
Table 1: Human cases in USA reported from 2004 to 2013
Year
Neuroinvasive disease Non-neuroinvasive disease Total
Cases Deaths Cases Deaths Cases Deaths
2004 6 2 1 0 7 2
2005 21 8 0 0 21 8
2006 8 5 0 0 8 5
2007 3 0 1 0 4 0
2008 4 1 0 0 4 1
2009 3 1 1 0 4 1
2010 10 5 0 0 10 5
2011 4 3 0 0 4 3
2012 15 5 0 0 15 5
2013 8 4 0 0 8 4
total 82 34 3 0 85 34
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EEEV was isolated from 67 out of 1551 equids studied including healthy individuals in the USA
during 1971 (Maness and Calisher, 1981). No other studies about the presence of the viruses in
healthy carriers are available.
Studies about transovarial transmission of EEEV in mosquitoes are conﬂicting and it seems this is
not an important overwintering mechanism for this virus (Scott and Weaver, 1989). However, WEEV
has been isolated from larvae of Aedes dorsalis mosquitoes (Fulhorst et al., 1994).
Although the common rule is that togaviruses can be inactivated by 15 min of heat at 56°C, Park
et al. (2016) have demonstrated that parameters such as temperature and time should be assayed
individually to establish the parameters needed for complete heat-inactivation in alphaviruses. In fact,
WEEV requires around 90 min to be completely inactivated at 56°C (Andrews and Turell, 2016). Like
other enveloped viruses, togaviruses are susceptible to disinfectants such as 1% sodium hypochlorite,
4% formaldehyde, 2% glutaraldehyde, 70% ethanol and 3–6% hydrogen peroxide. Alphavirus virions
are stable at pH 7–8. They are susceptible to radiant sunlight, moist or dry heat and drying, thus cool,
moist, dark conditions favours survival (OIE, 2013) but taking these data into consideration,
persistence of these viruses in environmental samples is negligible.
3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals, and, when relevant, between animals and humans
EEEV and WEEV are arboviruses whose transmission to human or animals is mediated by the bite of
an infected mosquito. No food-borne transmission has been described and only transmission from bird
to bird has been reported as described below. Data about the transmission rate or incidence between
animals and/or human are not available.
Culiseta melanura mosquitoes are the main vector for EEEV in North America although Culex spp.
(Culex peccator and Culex erraticus) and Uranotaenia sapphirina play a role in the maintenance of
enzootic cycles and some Aedes and Coquillettidia may act as bridge vectors. Culex (Melanoconion)
Table 2: Summary of the viraemic period determined in some species through experimental
infections
Species
Titre of viraemia
(pfu/ml)
Peak of
viraemia
Duration of
viraemia
Reference
EEEV Cotton rats (juvenile) 107–8 48 h 4–5 days Arrigo et al. (2010)
Cotton rats (mature) 104–5 48 h 3–4 days Arrigo et al. (2010)
House sparrows 105–7,5 24 h 3–4 days Arrigo et al. (2010)
Mice 107 or 109 Gardner et al. (2009)
Turkeys 106 24 h 2 days Guy et al. (1993)
Common marmosets
(SA strains)
102–3 24–48 h > 7 days Adams et al. (2008)
Common marmosets
(NA strains)
No Adams et al. (2008)
Green anole and
garter snake
102–5 7 days White et al. (2011)
Calf No Satriano et al. (1958)
Horse Yes 48 h Satriano et al. (1958)
Crow, great-horned
owl and pheasant
Yes 24–120 h Satriano et al. (1958)
Amphibians and
mammals
No Hayes et al. (1964)
Birds 1–4 days Hayes et al. (1964)
Reptiles 2–3 weeks Hayes et al. (1964)
Ponies Low Sponseller et al. (1966)
Donkeys About 103 1–2 days Byrne et al. (1964) and
Monath et al. (1985)
WEEV Blacktail jackrabbits 106.4 3 days Hardy et al. (1977)
Donkeys Low Byrne et al. (1964) and
Monath et al. (1985)
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are responsible for the transmission of MADV. Studies about transovarial transmission of EEEV in
mosquitoes are conﬂicting and it seems it is not an important overwintering mechanism for this virus
(Scott and Weaver, 1989). The virus has been also shown to be transmitted from captive bird to bird
orally mainly by pecking, feather picking or preening although cannibalism could also play a role (Acha
and Szyfres, 2003; Mesa et al., 2005; Estep et al., 2011). No other contact transmission experiments
or transplacental infection by EEEV have been reported.
WEEV is mainly transmitted by Culex tarsalis although A. dorsalis, Aedes campestris and
Ochlerotatus melanimon mosquitoes also play a role as bridge vectors (Acha and Szyfres, 2003; PHAC,
online). WEEV has been isolated from larvae of A. dorsalis mosquitoes (Fulhorst et al., 1994). No
contact transmission experiments or transplacental infection by WEEV have been reported. Mosquitos
species in which WEEV was detected and occurring in the European Union (EU) are A. dorsalis and
Aedes vexans: https://efsa.maps.arcgis.com/apps/MapJournal/index.html?appid=4f9f86684e3e465db
01ddf9cc557bac9 (EFSA AHAW Panel, 2017b,c).
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, and, where the disease is not present in the Union, the risk of its
introduction into the Union
Sporadic cases of infection by EEEV or WEEV occur in endemic regions although both viruses could
cause outbreaks or epidemics when susceptible animals or humans and infected mosquitoes coincide.
As for other arboviruses exotic in EU, the occurrence of sporadic cases, outbreaks or epidemics
depends on the control activities carried out if the virus goes into the territory.
EEEV and WEEV are not present in the EU. EEEV is widely distributed throughout North (eastern
part of USA and Canada), Central (Mexico, Cuba, Jamaica, the Dominican Republic) and South America
(Guyana, Colombia, Peru, Brazil, Argentina). WEEV is distributed along North (western part including
Canada and Mexico) and South America (Guyana, Brazil, Uruguay, Argentina). No clinical cases and no
imported cases have been ever reported in the EU.
The risk for entry of EEEV is through infected mosquitoes, infected birds or infected rodents and
amphibians and for WEEV also through infected mosquitoes or viraemic birds or rodents (Pfeffer and
Dobler, 2010).
Durand and colleagues (Durand et al., 2013) established that between 2005 and 2009 diverse
animals considered as potential hosts for EEEV or WEEV entered Europe. In Table 3, the numbers of
animal imports and the consignments (in brackets) of potential reservoir animals for these viruses are
shown (1 indicates risk for WEEV and 2 for EEEV).
The risk estimated for the entry of WEEV or EEEV in Europe estimated by Pfeffer and Dobler (2010)
is low, but due to the presence of passerine birds and small mammals and the relation of the viruses
with Culex pipiens and A. vexans autochthonous transmission could be established although the risk
for public or veterinary health are low. In another study, Durand et al. (2013) established the risk of
entry to Europe for EEEV and WEEV. The risk for WEEV is three times lower than for EEEV and the
consequences for health are also lower. For EEEV, the risk was attributed to exotic infected pets while
for WEEV was due to poultry. The Netherlands, the north of Italy and West France are the areas with
the highest risks for the entry of both viruses although Belgium and the South of England showed a
high risk for EEEV entry too.
Table 3: Number of animal imports and the consignments in Europe (Extracted from Durand et al.
(2013), data from TRACES)
Species
Origin of the animals
North America South America
Horses 15,703 (2,025)1
Poultry 15,5 M (518)1,2 61,945 (7)1,2
Other birds 391,348 (169)1,2 49,209 (160)1,2
Reptiles 5,881,321 (2,580)1 427,529 (605)1
Rodents 215,780 (5,879)1 448 (11)1
1: Consignments considered for EEEV emergence risk.
2: Consignments considered for WEEV emergence risk.
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The AHAW Panel assessed overall rate of introduction of EEEV as low and WEEV as very low in the
EU (EFSA AHAW Panel, 2017b), being the combination of the rate of entry of the pathogen, the level
of transmission and the establishment in the EU.
The duration of infectious period is linked to the duration of viraemia previously reported in section.
3.1.1.8. Scarce data are available about carrier status (see Section 3.1.1.5)
The main point to control the entry of these infections to the EU is the control of imported animals.
Recommendations for the importation of equines are that veterinary authorities of importing countries
should require an international veterinary certiﬁcate attesting that the animals: showed no clinical sign
of equine encephalomyelitis on the day of shipment and during the 3 months prior to shipment;
animals were kept for the three months prior to shipment in an establishment where no case of equine
encephalomyelitis was ofﬁcially reported during that period; or animals were kept in a quarantine
station for the 21 days prior to shipment and were protected from insect vectors during quarantine
and transportation to the place of shipment; or animals were vaccinated not less than 15 days and not
more than one year prior to shipment (OIE, 2016a). Alternatively, at entering EU, equids from third
countries where these diseases are distributed, should present a ‘Health Certiﬁcate’ where vaccination
status or results from haemagglutination inhibition tests to western and eastern equine
encephalomyelitis performed on two occasions are shown.1
3.1.1.9. Article 7(a)(viii) The existence of diagnostic and disease control tools
Diagnostic tools
Parameter 1 – Existence of diagnostic tools
As for other arboviruses, the period of viraemia is short and the titre is low so polymerase chain
reaction (PCR) and/or viral isolation could be useful only if the sample was taken in acute phases of
the disease and the cold chain is well preserved. Isolates may sometimes be obtained from
cerebrospinal ﬂuid (CSF) or from brain tissue (either at necropsy or post-mortem needle biopsy). Direct
detection (and identiﬁcation) of the virus conﬁrms its presence. EEEV can usually be isolated from the
brain of horses during the ﬁrst 5 days of illness. WEEV is rarely isolated from tissues of infected
horses. The most commonly used cell cultures are primary chicken or duck embryo ﬁbroblasts,
continuous cell lines of African green monkey kidney (Vero), rabbit kidney (RK-13), or baby hamster
kidney (BHK-21) and the newborn mouse and the chicken embryo systems are also useful.
Identiﬁcation of the virus can be carried out by complement ﬁxation, direct immunoﬂuorescent
staining, antigen-capture enzyme-linked immunosorbent assay (ELISA), immunohistochemical
procedures or using the neutralisation test. Reverse-transcription polymerase chain reaction (RT-PCR)
methods to detect EEE, WEE and VEE viral nucleic acid in mosquitoes and vertebrate tissues have
been described, although few have been extensively validated for mammalian samples. These tools
can also be used for direct identiﬁcation using clinical samples but with a lesser sensitivity (OIE, 2013;
CFSPH, 2015).
Detection of immunoglobulin M (IgM) in CSF samples could be also conﬁrmatory although infection
by other alphaviruses should be ruled out by epidemiological criteria and/or laboratory discrimination
of the presence of antigenically related alphaviruses. Neutralisation of viral growth based-techniques
are needed to do that. If no CSF is available and only serum samples are available, two samples taken
14 days apart are required to see a fourfold rise in the antibodies titre against each virus. Most horses
infected with EEEV or WEEV have a high antibody titre when clinical disease is observed so, a
presumptive diagnosis can be made if an unvaccinated horse with appropriate clinical signs has
antibody against only EEEV or WEEV. The detection of IgM antibody by ELISA can also provide a
presumptive diagnosis of acute infection. The haemagglutination inhibition test, complement ﬁxation
(CF) and other techniques can be used. CF antibody against both EEEV and WEEV appears later and
does not persist; consequently, it is less useful for the serological diagnosis of disease. Previous
vaccination can also interfere with interpretation of results so a good clinical history and two paired
sera samples and/or CSF for IgM or direct detection are needed (OIE, 2013; CFSPH, 2015).
1 Commission Decision 93/197/EEC of 5 February 1993 on animal health conditions and veterinary certiﬁcation for imports of
registered equidae and equidae for breeding and production. OJ L 86, 6.4.1993, p. 16-33.
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So, methods suitable for EEEV and/or WEEV diagnosis are
a) Direct detection
a. viral isolation
b. RT-PCR
c. CF
d. direct immunoﬂuorescent staining
e. antigen-capture ELISA
f. immunohistochemical procedures
g. neutralisation test.
b) Antibody detection
a. detection of IgM in CSF samples or in serum
b. haemagglutination inhibition tests
c. CF.
Control tools
Parameter 2 – Existence of control tools
Methods for preventing transmission:
Activities for control of these infections are individual prevention of mosquito bites by using
protective clothing and repellents, control of vectors and vaccination of equines and some avian
species. Surveillance using birds is also recommended.
Vaccination:
Regarding equine vaccination (in some cases EEEV vaccine is used in some birds), there is no effect
of the vaccination in human health since equids are not good ampliﬁers for the virus.
EEE/WEE vaccines currently available are formalin-inactivated adjuvanted whole virus products and
are distributed in different combinations as vaccines against EEEV and WEEV or adding also VEE and
other agents for use in horses. These formalin-inactivated preparations were shown to be highly
efﬁcacious in protecting against clinical disease but the EEE vaccine preparation is made with a North
American strain and it seems that they do not protect against South American strains (Dietz et al.,
1980; Strizki and Repik, 1995). Other approaches to obtain second generation vaccines exists (Minke
et al., 2004; Arechiga-Ceballos and Aguilar-Setien, 2015).
The availability of licensed vaccine products combined with an inability to completely eliminate risk
of exposure justiﬁes immunisation against EEE and WEE as core prophylaxis for all horses residing in
or travelling to North America and any other geographic areas where EEE and/or WEE is endemic
(Acha and Szyfres, 2003; AAEP, online).
3.1.2. Article 7(b) The impact of diseases
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The viruses are circulating only in the Western hemisphere. No presence in EU.
Outbreaks of EEEV can cause important loss in the equine industry as demonstrated by epidemics
in 1938 in USA when the virus affected 185,000 horses or in Louisiana in 1947, where 14,334 horses
were affected and the mortality rate was 83% (Hubalek et al., 2014). From 1956 to 1970, EEEV was
identiﬁed in USA in 605 encephalitic horses out of 2620 analysed (Acha and Szyfres, 2003). WEEV, in a
minor extension, can also cause disease in horses and 6000 equine cases were recorded in California
(1930) with a mortality of 50%, and epidemics occurred in Canada in 1937 and 1938 with a mortality
of 28% affecting 12,000 and 52,000 horses respectively (Hubalek et al., 2014). Also in the USA,
174,000 horses in 1937 and 184,000 in 1938 were affected by WEEV or EEEV and between 1956 and
1970, WEEV was isolated in 2015 encephalitic horses out of 2,620 analysed (Acha and Szyfres, 2003).
The economic impact for horses is not well established. As an example for other viruses such as
West Nile Virus in USA, an epidemic caused 569 cases in horses with 22% mortality in North Dakota.
Losses resulted in costs of US$ 1.5 million spent in medical services and due to inability to use horses
for recreation purposes because of the disease (Ndiva Mongoh et al., 2008).
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3.1.2.2. Article 7(b)(ii) The impact of the disease on human health
Humans get infected by the bite of an infected mosquito. No other route of transmission has been
demonstrated. Infections could occur as sporadic cases, small outbreaks or epidemics if not controlled.
Most human infections by EEEV are asymptomatic, but when CNS involvement occurs, it results in
frequent and severe neurological signs, lesions, and sequelae. The mortality rate associated to human
cases of EEE varies from 50% to 75% and the young are at greater risk of clinical disease. The early
clinical illness involves a ﬂu-like prodromal stage of about 5 days dominated by high fever and
headache and death can occur within 3–5 days of infection (Calisher, 1994). Children commonly exhibit
facial oedema. Paresis, paralysis, respiratory impairment, altered mental state and seizures are
common neurological manifestations and many of these signs persist for long periods in patients who
survive the acute illness. Survivors suffer from neurological sequelae, including convulsions, paralysis,
and mental retardation.
WEEV causes asymptomatic or mild infections in humans, with non-speciﬁc symptoms such as
sudden onset of fever, headache, nausea, vomiting, anorexia and malaise. Some patients may also
present with altered mental status and weakness, with signs of meningeal irritation. The infection may
cause encephalitis or encephalomyelitis, resulting in neck stiffness, confusion, visual disturbances,
photophobia, tonic-clonic seizures, somnolence, coma, and death in rare cases. An estimated 90% of
humans with WEE under the age of 1 year show severe CNS signs (Calisher, 1994). Estimates of the
case fatality rate of WEE range from 3% to 15%. Fifteen to ﬁfty per cent of the encephalitis survivors,
especially young children, suffer from permanent neurological damage (mental retardation, emotional
instability and spastic paresis). The mortality rate of a few cases of aerosolised WEE in humans, as those
occurred in laboratory workers, was 40% (Hanson et al., 1967). WEEV has mortality range of 3–7%.
Neurological sequelae (confusion, visual disturbances, photophobia, seizures, somnolence, coma,
intellectual disability, and emotional instability/behavioural changes and spastic paresis) in 15–30% of
WEE survivors have been described. In the case of EEE survivors, convulsions, seizures, paralysis,
intellectual disability and behavioural changes have been observed in 50–90% of the survivors (Ronca
et al., 2016).
No data about disability-adjusted life year (DALY) are available. There is no speciﬁc treatment
against these viruses and vaccines for humans are also recommended for laboratory workers or
military personnel.
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
The impact on animal welfare is not well established although during EEE outbreaks, many avian
species could develop illness with fever, ataxia, trembling, leg and generalised paralysis and death
(Scott and Weaver, 1989; Acha and Szyfres, 2003; Hubalek et al., 2014; CFSPH, 2015). For infected
horses, 80–90% develop acute and lethal disease, and about 66% of the survivors develop
neurological sequelae (Scott and Weaver, 1989) while for WEEV mortality is about 20–30% (Acha and
Szyfres, 2003; CFSPH, 2015).
3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
Many wild rodents, amphibians, reptiles and other animals could be infected by these viruses but
the viruses affect mainly equine and avian (mainly passerine birds) species. No data about the
susceptibility of European species are available. The mortality in due to infection with EEEV or WEEV of
wild animal species has not been calculated.
The non-controlled use of non-approved repellents for vector control could have some effect on the
environment but strict regulations should be applied. To assess the potential impact on the
environment of chemical biocidal products used to control potential outbreaks of vector-borne
diseases, information was extracted from ECHA’s website on approved active substances which may be
used for controlling the relevant vector species (EFSA AHAW Panel, 2017b). Any potential impact on
the environment of the use of biocidal products beyond the intended uses, doses and target species as
evaluated by European Chemicals Agency (ECHA) is unknown.
Persistence of EEEV or WEEV in the environment outside their hosts or vectors is not of concern.
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
EEEV and WEEV are included in the List of Human and Animal Pathogens and Toxins for Export
Control by the Australia group (AG, online). They are classiﬁed in the category B [viral encephalitis
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alphaviruses (e.g. VEE, EEE, WEE)] of CDC Bioterrorism Agents (CDC, online-b). EEEV, except the
South American genotype, is a select agent that requires registration with CDC and/or USDA for
possession, use, storage and/or transfer since it has the potential to pose a severe threat to public
health and safety, to animal and plant health, or to animal or plant products (CDC, online-a). Both
viruses are listed in the OIE list of notiﬁable terrestrial and aquatic animal diseases (OIE, online).
3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following
disease prevention and control measures
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities
On July 2011, only six countries (France, Germany, Italy, the Netherlands, Slovakia and Spain),
belonging to the European Network for the Diagnostic of Imported Viral Diseases (ENIVD), had
laboratories where speciﬁc detection of EEEV and/or WEEV could be carried out (ENIVD, online).
Methods available are in-house tests whose sensitivity and speciﬁcity need to be established.
There are no commercial, internationally recognised and/or OIE certiﬁed speciﬁc tools for diagnostic
of these viruses.
For human infections, diagnostic is carried out in CSF and/or serum samples. In the case of animal
infection, other tissues could be used including brain.
3.1.4.2. Article 7(d)(ii) Vaccination
Commercial vaccines based on inactivated virus are available for horse vaccination.
Testing of EEEV/WEEV vaccines was performed by intracranial challenge with either EEEV or WEEV;
the formalin-inactivated preparations were shown to be highly efﬁcacious in protecting against clinical
disease. Since vaccines do not confer long-lasting protection, vaccination against EEEV in the USA is
recommended once a year and in areas at high risk, more often (AAEP, online). Since EEEV vaccines are
against North American strains, they are not so effective against MADV (Dietz et al., 1980; Strizki and
Repik, 1995). Horses should be vaccinated twice a year against WEEV due to low immunogenicity (Barber
et al., 1978). Vaccines are administered by injecting 1 mL doses intramuscularly using aseptic
techniques. After the ﬁrst dose, a second one is recommended after 3–4 weeks. Later, yearly vaccination
(or more often in case of high risk) is recommended (Arechiga-Ceballos and Aguilar-Setien, 2015).
No vaccine for human use is available. Only vaccines to be used in horses are commercially
distributed but no vaccines have been authorised for use in the European Union by the European
Medicine Agency (EMA)2
3.1.4.3. Article 7(d)(iii) Medical treatments
No medical treatment is available for these infections.
3.1.4.4. Article 7(d)(iv) Biosecurity measures
Severe clinical disease or death can occur in humans and four laboratory-acquired cases of EEE and
seven cases of WEE (with two deaths) have been reported and the recommendation is that to work
with these viruses in a biosafety level 3 (BSL3) facility although a lesser biosafety level could be used
with diagnostic samples. If viral isolation is tried a BSL3 facility is needed (Anonymous, 1980).
Laboratories with suitable BSL facilities are available throughout Europe. However, access to diagnostic
tests is limited.
Due to the route of transmission (infected mosquitoes) of these viruses, biosecurity measures are
not a requirement in preventing the pathogen introduction in EU.
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products
No speciﬁc recommendation for restrictions of movements for EEEV and/or WEEV infected animals
is available. If a case is detected within EU, measures for vector control should be applied trying
to reduce vector numbers in an area by treatment and/or elimination of potential breeding sites.
Large-scale insecticide spraying is generally too costly, ineffective in the long-term, and/or
environmentally unacceptable. Other approaches might be to treat susceptible animals with long acting
insecticides during critical periods or remove animals from high-activity insect vector areas either
continuously or during times of the day or year when insect vectors are most active. If necessary,
zoning and compartmentalisation measures could be applied (OIE, 2016b).
2 http://www.ema.europa.eu/ema/
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3.1.4.6. Article 7(d)(vi) Killing of animals
Methods for killing of animals, if necessary, are compiled in (OIE, 2016c), no speciﬁc
recommendation for EEEV and/or WEEV infected animals are available.
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
Animal carcasses and products derived from EEEV and/or WEEV infected animals pose a negligible
transmission risk so no special measures are warranted (Williams, 2003).
3.1.5. Article 7(e) The impact of disease prevention and control measures
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
After the Texas WEE outbreak in 1971, the cost of infection per person was estimated as $320,000
(Earnest et al., 1971). The economic burden associated with patients suffering long-term sequelae due
to EEE was also determined. Hospital costs for the ﬁrst week of infection were approximately $21,000
but medical costs for someone suffering from long-term sequelae, would exceed $0.4 million per year
per individual, with costs reaching up to $3 million in the life span of the affected individual. The cost
of insecticidal prevention of mosquito vectors was estimated as $0.7–1.4 million dollars (Villari et al.,
1995).
As a general rule, a horse owner might save about 2 per cent of the annual cost by not inoculating
the horse with the core vaccines that includes WEEV and EEEV; however, the cost of not vaccinating
can far outweigh the potential savings (Scott, 2015).
Although no precise data are available for WEEV or EEEV, cost estimations for West Nile virus
affecting horses in Texas have been calculated by Galvan and colleagues (Galvan et al., online) and
they estimate the cost of vaccination as US$6,250,000 in 2002 and US$6,250,000 in 2003 while costs
of mortality of infected horses during 2002 was US$2,856,000 and during 2003 it was US$1,205,400.
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
No references have been found regarding this item.
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
One of the measures for control is avoiding mosquito bites and this could imply stabling of animals
so regulations should be followed.
Uncontrolled use of insecticides could affect some animal species but strict regulations should be
applied in case of need of using these compounds.
3.1.5.4. Article 7(e)(iv) The environment and biodiversity
Uncontrolled use of insecticides could affect environment and biodiversity but strict regulations
should be applied in case of need of using these compounds but no mortality in wild species because
of the control measures to be applied is expected.
3.2. Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL
about equine encephalomyelitis (Eastern and Western) (Table 4). The expert judgement was based on
Individual and Collective Behavioural Aggregation (ICBA) approach described in detail in the opinion on
the methodology (EFSA AHAW Panel, 2017a). Experts have been provided with information of the
disease fact-sheet mapped into Article 5 criteria (see supporting information, Annex A), based on that
the experts indicate their Y/N or ‘na’ judgement on each criterion of Article 5, and the reasoning
supporting their judgement.
The minimum number of judges in the judgement was 12. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017a). For details on the
interpretation of the questions see Appendix B of the methodological opinion (EFSA AHAW Panel,
2017a).
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3.2.1. Non-consensus questions
This section displays the assessment related to each criterion of Article 5 where no consensus was
achieved in form of tables (Tables 5 and 6). The proportion of Y, N or na answers are reported,
followed by the list of different supporting views for each answer.
Reasoning supporting the judgement
Supporting Yes:
• Considering the horse sector, if introduced, EEE and WEE may have a high impact due to their
epidemic potential and high mortality in horses.
• For the sector of race horses, even a low number of affected animals may result in very high
losses in terms of costs.
• Depending on the area where the disease is introduced, there could be a signiﬁcant impact
(i.e. foal markets). Even if one single infected animal is introduced, markets could be closed
(France as example).
• There may be a potential signiﬁcant economic impact considering production of race horses in
the absence of control measures (vector control or vaccination).
Table 4: Outcome of the expert judgement on the Article 5 criteria for equine encephalomyelitis
(Eastern and Western)
Criteria to be met by the disease:
According to AHL, a disease shall be included in the list referred to in point (b) of paragraph 1 of
Article 5 if it has been assessed in accordance with Article 7 and meets all of the following criteria
Final
outcome
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof exist in
the Union
Y
A(iii) The disease causes negative effects on animal health or poses a risk to public health due
to its zoonotic character
Y
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are effective and
proportionate to the risks posed by the disease in the Union
Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points A(i)–A(v), the disease needs to fulﬁl at least one of the
following criteria
B(i) The disease causes or could cause signiﬁcant negative effects in the Union on animal health,
or poses or could pose a signiﬁcant risk to public health due to its zoonotic character
Y
B(ii) The disease agent has developed resistance to treatments and poses a signiﬁcant danger
to public and/or animal health in the Union
na
B(iii) The disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union
NC
B(iv) The disease has the potential to generate a crisis or the disease agent could be used for the
purpose of bioterrorism
Y
B(v) The disease has or could have a signiﬁcant negative impact on the environment, including
biodiversity, of the Union
NC
Colour code: green = consensus (Yes/No); yellow = no consensus (NC); red = not applicable (na), i.e. insufﬁcient evidence or
not relevant to judge.
Table 5: Outcome of the expert judgement related to criterion 5 B(iii)
Question
Final
outcome
Response
Y (%) N (%) na (%)
B(iii) The disease causes or could cause a signiﬁcant negative
economic impact affecting agriculture or aquaculture production
in the Union
NC 83 17 0
NC: non-consensus; number of judges: 12.
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Supporting No:
• The opinion on vector-borne diseases (EFSA AHAW Panel, 2017b) indicates that the probability
of spread in the Union is low due to too low densities of vectors and hosts. Thus, the potential
impact can be considered to be low.
Reasoning supporting the judgement
Supporting No:
• The model in the scientiﬁc opinion on vector-borne diseases (EFSA AHAW Panel, 2017b) suggests
that the impact of these diseases on the environment and biodiversity is likely to be low.
Supporting na:
• Cases in the US are well-known and there is no signiﬁcant impact, but it is difﬁcult to infer how
the disease would behave in completely different ecosystems in the EU.
• There is a lack of information concerning the susceptibility of the European bird population.
3.2.2. Outcome of the assessment of equine encephalomyelitis (Eastern and
Western) according to criteria of Article 5(3) of the AHL on its eligibility to
be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria of the ﬁrst set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017a), a criterion is
considered fulﬁlled when the outcome is ‘Yes’. According to the results shown in Table 4, equine
encephalomyelitis (Eastern and Western) complies with all criteria of the ﬁrst set and with two criteria
of the second set, therefore it is considered eligible to be listed as laid down in Article 5 of the AHL.
3.3. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about equine encephalomyelitis (Eastern and Western) (Tables 7–11).
The expert judgement was based on ICBA approach described in detail in the opinion on the methodology.
Experts have been provided with information of the disease fact-sheet mapped into Article 9 criteria (see
supporting information, Annex A), based on that the experts indicate their Y/N or ‘na’ judgement on each
criterion of Article 9, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 12. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017a). For details on the
interpretation of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel,
2017a).
Table 6: Outcome of the expert judgement related to criterion 5 B(v)
Question
Final
outcome
Response
Y (%) N (%) na (%)
B(v) Disease has or could have a signiﬁcant negative impact
on the environment, including biodiversity, of the Union
NC 0 58 42
NC: non-consensus; number of judges: 12.
Table 7: Outcome of the expert judgement related to the criteria of Section 1 of Annex IV
(category A of Article 9) for equine encephalomyelitis (Eastern and Western)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is not present in the territory of the Union OR present only in exceptional cases
(irregular introductions) OR present in only in a very limited part of the territory of the Union
Y
2.1 The disease is highly transmissible N
2.2 There be possibilities of airborne or waterborne or vector-borne spread Y
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2.3 The disease affects multiple species of kept and wild animals OR single species of kept
animals of economic importance
Y
2.4 The disease may result in high morbidity and signiﬁcant mortality rates Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, including
epidemic or pandemic potential OR possible signiﬁcant threats to food safety
N
4 The disease has a signiﬁcant impact on the economy of the Union, causing substantial costs,
mainly related to its direct impact on the health and productivity of animals
N
5(a) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large numbers
of animals
NC
5(c) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
na
5(d) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection of
endangered species or breeds, including the possible disappearance or long-term damage to
those species or breeds
NC
Colour code: green = consensus (Yes/No); yellow = no consensus (NC); red = not applicable (na), i.e. insufﬁcient evidence or not
relevant to judge.
Table 8: Outcome of the expert judgement related to the criteria of Section 2 of Annex IV
(category B of Article 9) for equine encephalomyelitis (Eastern and Western)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic character
AND (at the same time) several Member States or zones of the Union are free of the disease
N
2.1 The disease is moderately to highly transmissible Y
2.2 There be possibilities of airborne or waterborne or vector-borne spread Y
2.3 The disease affects single or multiple species Y
2.4 The disease may result in high morbidity with in general low mortality N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, including
epidemic potential OR possible signiﬁcant threats to food safety
N
4 The disease has a signiﬁcant impact on the economy of the Union, causing substantial costs,
mainly related to its direct impact on the health and productivity of animals
N
5(a) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large numbers
of animals
NC
5(c) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
na
5(d) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection of
endangered species or breeds, including the possible disappearance or long-term damage to
those species or breeds
NC
Colour code: green = consensus (Yes/No); yellow = no consensus (NC); red = not applicable (na), i.e. insufﬁcient evidence or not
relevant to judge.
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3.3.1. Non-consensus questions
This section displays the assessment related to each criterion of Annex IV referring to the
categories of Article 9 of the AHL where no consensus was achieved in form of tables (Tables 12–14).
The proportion of Y, N or ‘na’ answers are reported, followed by the list of different supporting views
for each answer.
Table 9: Outcome of the expert judgement related to the criteria of Section 3 of Annex IV
(category C of Article 9) for equine encephalomyelitis (Eastern and Western)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic character N
2.1 The disease is moderately to highly transmissible Y
2.2 The disease is transmitted mainly by direct or indirect transmission Y
2.3 The disease affects single or multiple species Y
2.4 The disease usually does not result in high morbidity and has negligible or no mortality AND
often the most observed effect of the disease is production loss
N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, or
possible signiﬁcant threats to food safety
Y
4 The disease has a signiﬁcant impact on the economy of parts of the Union, mainly related to
its direct impact on certain types of animal production systems
Y
5(a) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large numbers
of animals
NC
5(c) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
na
5(d) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection of
endangered species or breeds, including the possible disappearance or long-term damage to
those species or breeds
NC
Colour code: green = consensus (Yes/No); yellow = no consensus (NC); red = not applicable (na), i.e. insufﬁcient evidence or not
relevant to judge.
Table 10: Outcome of the expert judgement related to the criteria of Section 4 of Annex IV
(category D of Article 9) for equine encephalomyelitis (Eastern and Western)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
D The risk posed by the disease in question can be effectively and proportionately mitigated by
measures concerning movements of animals and products in order to prevent or limit its
occurrence and spread
NC
The disease fulﬁls criteria of Sections 1, 2, 3 or 5 of Annex IV of AHL Y
Colour code: green = consensus (Yes/No); yellow = no consensus (NC).
Table 11: Outcome of the expert judgement related to the criteria of Section 5 of Annex IV
(category E of Article 9) for equine encephalomyelitis (Eastern and Western)
Diseases in category E need to fulﬁl criteria of Sections 1, 2 or 3 of Annex IV of AHL
and/or the following:
Final
outcome
E Surveillance of the disease is necessary for reasons relating to animal health, animal welfare,
human health, the economy, society or the environment
(If a disease fulﬁls the criteria as in Article 5, thus being eligible to be listed, consequently
category E would apply.)
Y
Colour code: green = consensus (Yes/No).
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Reasoning supporting the judgement
Supporting Yes:
• If introduced in the EU and in the absence of control measures, the animal welfare impact
would be signiﬁcant.
• High morbidity with severe clinical signs (neurological sequelae) has been described.
• There is potential for signiﬁcant animal welfare impact. Outbreaks of EEE in horses in North
America have been common and often accompanied by high case fatality rates: 80–90% of the
infected horses developed acute and lethal disease, and about 66% of the survivors developed
neurological sequelae (Scott and Weaver, 1989). The mortality is lower for WEEV, which
generally causes a mild disease but in some cases, symptoms of altered mental status,
weakness and signs of meningeal irritation occur and a minority of infected individuals develop
encephalitis or encephalomyelitis.
Supporting No:
• The animal welfare impact is not considered to affect large numbers of animals.
• Based on the model as in the scientiﬁc opinion on vector-borne diseases (EFSA AHAW Panel,
2017b), the likelihood of animal welfare impact for large numbers in the EU is low.
Supporting na:
• There may be an impact on animal welfare for the affected horses but it is difﬁcult to state
that this would be on ‘large numbers’.
• In the USA, there have been large epizootics, but the model in the scientiﬁc opinion on vector-
borne diseases (EFSA AHAW Panel, 2017b) showed that for EEEV there was a very low to low
rate of introduction, and subsequently, a very low extent of annual spread. The latter had high
uncertainty due to the high uncertainty related to the efﬁcacy of the control measures to
contain the spread. The annual extent of spread of WEEV has not been assessed, as the
overall rate of introduction was estimated to be very low (EFSA AHAW Panel, 2017b).
Reasoning supporting the judgement
Supporting No:
• In the scientiﬁc opinion on vector-borne diseases (EFSA AHAW Panel, 2017b), the disease spread
and impact was not assessed for WEE due to very low rate of introduction and only low extent of
spread was assessed for EEE. According to that, there is no signiﬁcant impact on biodiversity.
Table 12: Outcome of the expert judgement related to criterion 5(b) of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
5(b) The disease has a signiﬁcant impact on animal welfare, by
causing suffering of large numbers of animals
NC 50 33 17
NC: non-consensus; number of judges: 12.
Table 13: Outcome of the expert judgement related to criterion 5(d) of Article 9
Question
Final
outcome
Response
Y (%) N (%)
na
(%)
5(d) The disease has a signiﬁcant impact on a long-term effect on
biodiversity or the protection of endangered species or breeds,
including the possible disappearance or long-term damage to those
species or breeds
NC 0 25 75
NC: non-consensus; number of judges: 12.
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Supporting na:
• There is evidence available in the US, but it is difﬁcult to determine how the disease would
behave in a different ecosystem in the EU.
• No information is available on susceptibility of wild species (e.g. birds or rodents) in the EU.
• It is uncertain whether there would be an impact with a long-term effect on biodiversity.
Reasoning supporting the judgement
Supporting Yes:
• Movement restrictions and regulations on import of reservoir animals (i.e. birds, reptiles,
rodents and amphibian) into the EU can reduce the introduction and spread of these
infections, although may not be totally effective in preventing it.
Supporting No:
• Controls in imported animals may not be sufﬁciently effective in totally preventing disease
introduction and trade of ornamental birds could pose a serious risk, because the quarantine
or testing of these species is not feasible. Movement control measures would not prevent
spread of the disease by mosquitoes and wild birds.
3.3.2. Outcome of the assessment of criteria in Annex IV for equine
encephalomyelitis (Eastern and Western) disease for the purpose of
categorisation as in Article 9 of the AHL
As from the legal text of the AHL, a disease is considered ﬁtting in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulﬁls all criteria of the ﬁrst set from 1 to 2.4 and at least
one of the second set of criteria from 3 to 5(d) as shown in Tables 7–11. According to the assessment
methodology (EFSA AHAW Panel, 2017a), a criterion is considered fulﬁlled when the outcome is ‘Yes’.
A description of the outcome of the assessment of criteria in Annex IV for equine encephalomyelitis
(Eastern and Western) for the purpose of categorisation as in Article 9 of the AHL is presented in
Table 15.
Table 14: Outcome of the expert judgement related to criterion D of Article 9
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
D The risk posed by the disease in question can be effectively and
proportionately mitigated by measures concerning movements of animals
and products in order to prevent or limit its occurrence and spread
NC 33 67 0
NC: non-consensus; number of judges: 12.
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According to the assessment here performed, equine encephalomyelitis (Eastern and Western)
complies with the following criteria of the Sections 1–5 of Annex IV of the AHL for the application of
the disease prevention and control rules referred to in points (a) to (e) of Article 9(1):
1) To be assigned to category A, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment equine encephalomyelitis (Eastern and
Western) complies with criteria 1, 2.2, 2.3 and 2.4, but not with 2.1. To be eligible for
category A, a disease needs to comply additionally with one of the criteria of the second set
(3, 4, 5a–d) and equine encephalomyelitis (Eastern and Western) does not comply with
criteria 3, 4 and 5a, the assessment is inconclusive on compliance with criteria 5b and 5d
and not applicable on criterion 5c.
2) To be assigned to category B, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment equine encephalomyelitis (Eastern and
Western) complies with criteria 2.1, 2.2 and 2.3, but not with criteria 1 and 2.4. To be
eligible for category B, a disease needs to comply additionally with one of the criteria of the
second set (3, 4, 5a–d) and equine encephalomyelitis (Eastern and Western) does not
comply with criteria 3, 4 and 5a, the assessment is inconclusive on compliance with criteria
5b and 5d and not applicable on criterion 5c.
3) To be assigned to category C, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1-2.4) and according to the assessment equine encephalomyelitis (Eastern and
Western) complies with criteria 2.1, 2.2 and 2.3, but not with criteria 1 and 2.4. To be
eligible for category C, a disease needs to comply additionally with one of the criteria of the
second set (3, 4, 5a–d) and equine encephalomyelitis (Eastern and Western) complies with
criteria 3 and 4, but not with criterion 5a, the assessment is inconclusive on compliance with
criteria 5b and 5d and not applicable on criterion 5c.
4) To be assigned to category D, a disease needs to comply with criteria of Sections 1, 2, 3 or 5
of Annex IV of the AHL, with which equine encephalomyelitis (Eastern and Western)
complies, and with the speciﬁc criterion D of Section 4, with which the assessment on equine
encephalomyelitis (Eastern and Western) is inconclusive.
5) To be assigned to category E, a disease needs to comply with criteria of Sections 1, 2 or 3 of
Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating
to animal health, animal welfare, human health, the economy, society or the environment.
The latter is applicable if a disease fulﬁls the criteria as in Article 5, with which equine
encephalomyelitis (Eastern and Western) complies.
Table 15: Outcome of the assessment of criteria in Annex IV for equine encephalomyelitis (Eastern
and Western) for the purpose of categorisation as in Article 9 of the AHL
Category
Article 9 criteria
1° set of criteria 2° set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
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3.4. Assessment of Article 8
This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about
equine encephalomyelitis (Eastern and Western). The Article 8(3) criteria are about animal species to
be listed, as it reads below:
‘3. Animal species or groups of animal species shall be added to this list if they are affected or if
they pose a risk for the spread of a speciﬁc listed disease because:
a) they are susceptible for a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that
such role is likely’.
For this reason, the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also possible role of biological or mechanical vectors.3 According to the
mapping, as presented in Table 5, Section 3.2 of the scientiﬁc opinion on the ad hoc methodology
(EFSA AHAW Panel, 2017a), the main animal species to be listed for equine encephalomyelitis (Eastern
and Western) according to the criteria of Article 8(3) of the AHL are as displayed in Tables 16 and 17.
Table 16: Main animal species to be listed for Eastern equine encephalomyelitis according to
criteria of Article 8 (source: data reported in Sections 3.1.1.1 and 3.1.1.6)
Class Order Family Genus/Species
Susceptible Mammalia Artiodactyla Cervidae Odocoileus virginianus
Suidae Sus scrofa
Bovidae Bos taurus, Ovis aries
Perissodactyla Equidae Equus caballus, Equus asinus
Carnivora Canidae Canis lupus
Rodentia Muridae Mus muris
Aves Sphenisciformes Spheniscidae Spheniscus demersus
Passeriformes Passeridae not speciﬁed
Corvidae not speciﬁed
Casuariiformes Dromaiidae Dromaius spp.
Strigiformes Strigidae Bubo virginianus
Galliformes Phasianidae Phasianus spp., Meleagris spp.
Reptilia Squamata Polychrotidae Carolina anole (Anolis carolinensis)
Colubridae Garter snake (Thamnophis sirtalis)
Amphibia Not speciﬁed
Reservoir Aves Passeriformes
Mammalia Rodentia not speciﬁed
Marsupialia not speciﬁed
Vectors Insecta Diptera Culicidae Culiseta melanura, Culex (Melanoconion)
3 A vector is a living organism that transmits an infectious agent from an infected animal to a human or another animal. Vectors
are frequently arthropods. Biological vectors may carry pathogens that can multiply within their bodies and be delivered to new
hosts, usually by biting. In mechanical vectors the pathogens do not multiply within the vector, which usually remains infected
for shorter time than in biological vectors.
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4. Conclusions
TOR 1: for each of those diseases an assessment, following the criteria laid down in Article 7 of
the AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3) of the AHL;
• According to the assessment here performed, equine encephalomyelitis (Eastern and Western)
complies with all criteria of the ﬁrst set and with two criteria of the second set and therefore
can be considered eligible to be listed for Union intervention as laid down in Article 5(3) of the
AHL.
TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an
assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL;
• According to the assessment here performed, equine encephalomyelitis (Eastern and Western)
meets the criteria as in Section 5 of Annex IV of the AHL, for the application of the disease
prevention and control rules referred to in point (e) of Article 9(1) of the AHL. According to the
assessment here performed, it is inconclusive whether equine encephalomyelitis (Eastern and
Western) complies with the criteria as in Section 4 of Annex IV of the AHL, for the application
of the disease prevention and control rules referred to in point (d) of Article 9(1) of the AHL.
Compliance of equine encephalomyelitis (Eastern and Western) with the criteria as in Section 4
is dependent on a decision on criterion D.
TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list
of animal species that should be considered candidates for listing in accordance with Article 8 of the
AHL.
• According to the assessment here performed, the animal species that can be considered to be
listed for equine encephalomyelitis (Eastern and Western) according to Article 8(3) of the AHL
are several species of mammals, birds, reptiles and amphibians as susceptible species; rodents,
lagomorphs and several bird species as reservoirs and at least four mosquito species (family
Culicidae) as vectors, as reported in Tables 16 and 17 in Section 3.4 of the present document.
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PCR polymerase chain reaction
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